left-arrow right-arrow pinterest facebook google_plus linkedin

Alliance A041701

Status:

Recruiting | Phase II/III

Official Title:

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Study Purpose:

To compare the usual treatment alone to using uproleselan plus the usual treatment.

Interventions:

  • Group 1: Daunorubicin + Cytarabine (usual approach group)
  • Group 2: Daunorubicin + Cytarabine + Uproleselan (study drug)

Patients will either get the usual treatment or the usual treatment plus the study drug for up to 5 months. After treatment is finished the doctor will continue to follow up and watch for side effects for up to 5 years.

Key Participation Requirements:

Gender:

Male or Female

Age:

60 years and older

Diagnosis:

Acute Myeloid Leukemia

Eligibility:

No prior chemotherapy for MDS or AML

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

Alliance A041701

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!